肖格伦综合征的认知障碍:BACE1活性,炎症血液生物标志物和神经认知测试之间的相互作用
Alireza Kooshki1, Mohammad Yousefi1, Reyhane Farmani1
1Student Research Committee, Birjand University of Medical Sciences, Birjand, Iran.
PloS one
|August 1, 2025
概括
斯约格伦综合征患者表现出认知能力下降,但关键生物标志物如BACE1和炎症标志物保持不变. 需要进行进一步的研究,以了解Sjogren综合征中神经认知障碍背后的机制.
科学领域:
- 神经免疫学 神经免疫学
- 自身免疫性疾病 自身免疫性疾病
- 认知科学 认知科学
背景情况:
- 斯乔格伦综合征 (SS) 是一种慢性自身免疫性疾病,具有多种表现,包括神经复杂症.
- 认知功能障碍是SS患者的一个显著的神经复杂症.
研究的目的:
- 为了评估Sjogren综合征患者的认知功能障碍.
- 研究认知功能与SS中的特定生物标志物之间的关系.
主要方法:
- 一项研究使用认知测试和血液分析将44名SS患者与37名对照人进行了比较.
- 测量了BACE1,IL-6,TAC,NO和MDA的血清水平.
- 使用PRISM 10和SPSS 22进行了统计分析.
主要成果:
- 斯约格伦综合征患者在MoCA和SDLT认知测试中得分明显较低.
- 血清BACE1,IL-6,NO,TAC和MDA水平在SS患者和对照人群之间没有差异.
- 诸如甲醇,化和普得尼松之类的药物影响了白血球计数和甘油三水平,而不是神经认知因素.
- IL-6与症状持续时间有很强的相关性,BACE1与IL-6水平有积极的相关性.
结论:
- 在SS患者中,认知能力下降是显而易见的,但由于BACE1和炎症标志物没有改变,因此需要进一步调查潜在机制.
- 通常使用的药物 (MTX,HCQ,普雷尼松) 在本研究中没有影响神经认知结果.
- 该研究发现了血液学参数和认知测试之间的显著相关性,为SS提供了新的见解.
更多相关视频
07:08A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
7.9K
10:50Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo
Published on: March 26, 2019
7.8K
相关概念视频
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
40
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
40
Alzheimer's Disease: Overview
669
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
669
